Year: 2012
Type: article
Abstract: Synucleinopathies like Parkinson disease and dementia with Lewy bodies (DLB) are characterized by α-synuclein aggregates within neurons (Lewy bodies) and their processes (Lewy neurites). Whereas α-synuclein has been genetically linked to the disease process, the pathological relevance of α-synuclein aggregates is still debated. Impaired degradation is considered to result in aggregation of α-synuclein. In addition to the ubiquitin-proteasome degradation, the autophagy-lysosomal pathway (ALP) is involved in intracellular degradation processes for α-synuclein. Here, we asked if modulation of ALP affects α-synuclein aggregation and toxicity. We have identified an induction of the ALP markers LAMP-2A and LC3-II in human brain tissue from DLB patients, in a transgenic mouse model of synucleinopathy, and in a cell culture model for α-synuclein aggregation. ALP inhibition using bafilomycin A 1 (BafA1) significantly potentiates toxicity of aggregated α-synuclein species in transgenic mice and in cell culture. Surprisingly, increased toxicity is paralleled by reduced aggregation in both in vivo and in vitro models. The dichotomy of effects on aggregating and nonaggregating species of α-synuclein was specifically sensitive to BafA1 and could not be reproduced by other ALP inhibitors. The present study expands on the accumulating evidence regarding the function of ALP for α-synuclein degradation by isolating an aggregation specific, BafA1-sensitive, ALP-related pathway. Our data also suggest that protein aggregation may represent a detoxifying event rather than being causal for cellular toxicity.
Source: Autophagy
DOI: 10.4161/auto.19371
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Parkinson's Disease Foundation, Bundesministerium für Bildung und Forschung, Bayerisches Staatsministerium für Wissenschaft, Forschung und Kunst, Bayerisch-Kalifornischen Hochschulzentrum, National Institutes of Health, National Institute on Aging, National Institute of Neurological Disorders and Stroke
Awards: Gene Therapy for Alzheimer's Disease, a-synuclein clearance strategies for the treatment of Lewy body disease, G2937085932, a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease, UCSD Alzheimer's Disease Research Center P50, G3430563080, G3457996028, La Jolla Interdisciplinary Neuroscience Center Cores, G486772123, MGH/MIT MORRIS UDALL CENTER OF EXCELLENCE IN PD RESEARCH, Proteinopathies of the Aging Central Nervous System, G8703175033, Verbundvorhaben Integration von aus Stammzellen bebildeten Neuronen: Integration in das Striatum (TP5), G8880870205
OpenAlex ID: W2055652883
